Preclinical Evaluation of an Anti-CD41 CAR T Cell in Acute Megakaryoblastic Leukemia on in Vitro and In Vivo Models

Acute Megakaryoblastic Leukemia (AMkL) is a rare disease that represents 5% of all reported AML cases and is diagnosed with high frequency in children with Down Syndrome and elderly people. M7-AMkL is characterized by a low overall survival and the patients have poor outcome to treatment, thus alternative treatments, such as CAR T cell therapies, are a need for better patient management.Herein, we present an evaluation of a new CAR T cell which targets CD41 marker, a specific surface antigen for M7-AMkL, in a preclinical model for AMkL using DAMI Luc2 cell line for in vitro and in vivo experiments.

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Adrian Bogdan Tigu, Catalin Constantinescu, Patric Teodorescu, David Kegyes, Raluca Munteanu, Richard Feder, Mareike Peters, Ioana Pralea, Cristina Iuga, Diana Cenariu, Andra Marcu, Alina Daniela Tanase, Anca Colita, Rares Drula, Jon Thor Bergthorsson, Vi Tags: 117 Source Type: research